The analyst believes expectations for Insmed's Ph II Nontuberculous Mycobacteria lung infection study are too high and the design suggests there will not be sufficient data for FDA approval and that a subsequent Ph III study will be needed. The firm's new launch date is mid-2018 vs previous expectations of early 2016 and the price target on shares has been reduced to $7 from $18
I would take a breather if I were you after your post this morning about that non-existing downgrade. You only add fuel to the fire for possible legal actions by Insmed or serious investors. Play with your money....not ours. There are folks here with the assets to protect their investments.